Dr. Reddy's launches new study of Russian COVID-19 vaccine in India

 

• Dr. Reddy's Laboratories (NYSE:RDY) announces the start of an adaptive Phase 2/3 clinical trial in India evaluating Russia's Sputnik V COVID-19 vaccine. The study will be conducted by JSS Medical Research.
• An adaptive study allows for modifications to the trial and/or statistical models while the study is in process.
• The company is partnering with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC’s clinical trial centers for the vaccine.
• The Russian Direct Investment Fund (RDIF) recently announced the results from the second interim analysis of a large-scale Phase 3 study that showed 91.4% efficacy at day 28 after the first dose and over 95% 42 days after the first dose. Over 40K volunteers are participating.
• In September, RDY and RDIF entered into a partnership to conduct clinical trials of the vaccine and the rights for distribution of the first 100 million doses in India.
• https://seekingalpha.com/news/3640378-dr-reddys-launches-new-study-of-russian-covidminus-19-vaccine-in-india